98%
921
2 minutes
20
Background: The incidence of adverse events and desaturation during airway-securing procedures (a sequence from preoxygenation to completion of tracheal intubation or supraglottic airway placement) under general anesthesia in children remains underexplored. Thus, this study investigated the incidence of adverse and desaturation events and associated risk factors.
Methods: This was a prospective, multicenter, observational study conducted between June 2022 and January 2024 in 10 tertiary care (6 pediatric and 4 university [mixed adult-pediatric]) hospitals in Japan. A standardized data collection system was applied through the recruited institutions to collect 95% or more of cases. The primary and secondary outcomes were adverse events and a 10% or greater drop in oxygen saturation (desaturation) associated with airway-securing procedures.
Results: There were 17,007 airway management procedures in 16,695 children (mean ± SD age, 6.3 ± 4.8 yr). Any adverse events occurred in 346 of 17,007 (2.0%; 95% CI, 1.8 to 2.3) children, including 189 of 17,007 (1.1%; 0.96 to 1.3) respiratory adverse events. Desaturation occurred during 395 of 17,007 (2.3%; 2.1 to 2.6) procedures, with 66 of 308 (21.4%; 17.0 to 26.4) in neonates and 210 of 2,298 (9.1%; 8.0 to 10.4) in infants. Multilevel regression analysis showed younger age (adjusted odds ratio, 0.92; 95% CI, 0.90 to 0.95; P < 0.001), airway management in radiation diagnostic/therapy rooms (5.7, 1.64 to 19.9; P = 0.006), airway sensitivity (1.46, 1.09 to 1.94; P = 0.010), craniocervical surgery (1.41, 1.09 to 1.83; P = 0.009), and presence of one anatomical difficult airway feature (1.74, 1.02 to 2.95; P = 0.042) versus two or more anatomic difficult airway features (2.82, 1.21 to 6.6; P = 0.017) as risk factors of any adverse events. Supraglottic airway device usage at the first attempt (0.42, 0.288 to 0.62; P < 0.001) and muscle relaxant administration (0.62, 0.43 to 0.89; P = 0.009) showed beneficial effects.
Conclusion: s: The Japan Pediatric Difficult Airway in Anesthesia (J-PEDIA) study demonstrated adverse event and desaturation incidences and the impact of clinically relevant risk factors during airway-securing procedures in Asian children. This study can help anesthesiologists to identify high-risk children and create a safe airway-securing strategy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12416892 | PMC |
http://dx.doi.org/10.1097/ALN.0000000000005646 | DOI Listing |
Emerg Med Australas
October 2025
Australian Centre for Health Services Innovation, School of Public Health & Social Work, Queensland University of Technology, Brisbane, Queensland, Australia.
Reliably defining the risk of adverse in-flight events in aeromedical trauma patients could enable more informed pre-departure treatment and guide central asset allocation to achieve better system-level outcomes. Unfortunately, the current literature base specifically examining the in-flight period is sparse. Flight duration is often considered a proxy for the risk of in-flight deterioration; however, there is limited data to support this commonly held assumption.
View Article and Find Full Text PDFImmunotherapy
September 2025
aGuangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Rev Med Liege
September 2025
Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Liège, Belgique.
Tirzepatide is a unimolecular dual agonist of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, recently commercialized and reimbursed in Belgium for the treatment of type 2 diabetes (T2D). Because of the complementarity of action of the two incretins, tirzepatide showed, in a dose-dependent manner (5, 10 and 15 mg as a once-weekly subcutaneous injection), a better efficacy (greater reduction in HbA1c and body weight) compared with placebo, semaglutide 1 mg, basal insulin and preprandial boluses of insulin lispro in six studies of the SURPASS programme. Tirzepatide tolerance is almost similar to that of pure GLP-1 receptor agonists, with digestive adverse events, most often during the first weeks after initiation, which justifies the recommendation of progressive titration every four weeks.
View Article and Find Full Text PDFRev Med Liege
September 2025
Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Liège, Belgique.
Type 1 diabetes (T1D) is an autoimmune chronic disease that leads to the destruction of pancreatic beta cells and thus requires lifelong insulin therapy. Constraints and adverse events associated to insulin therapy are well known as well as the risk of long-term complications linked to chronic hyperglycaemia. Symptomatic T1D is preceded by a preclinical asymptomatic period, which is characterized by the presence of at least two auto-antibodies against beta cell without disturbances of blood glucose control (stage 1) or, in addition to immunological biomarkers, by the presence of mild dysglycaemia reflecting a defect of early insulin secretion (stage 2).
View Article and Find Full Text PDFCardiol Young
September 2025
Department of Pharmacy, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA.
Introduction: Neonates with ductal-dependent CHD rely on the patency of the ductus arteriosus to maintain circulation. Alprostadil is utilised to maintain ductal patency, although optimal dosing has not been determined. This study aims to describe alprostadil dosing in neonates with ductal-dependent CHD.
View Article and Find Full Text PDF